<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00099840</url>
  </required_header>
  <id_info>
    <org_study_id>PARTIS</org_study_id>
    <nct_id>NCT00099840</nct_id>
  </id_info>
  <brief_title>Procalcitonin Guided Antibiotic Use in Acute Respiratory Tract Infections (PARTI)-Study</brief_title>
  <official_title>Procalcitonin Guided Antibiotic Use in Acute Respiratory Tract Infections in Primary Care - A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Basel Institute of Clinical Epidemiology (BICE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brahms AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <brief_summary>
    <textblock>
      Acute respiratory tract infections (ARTI) are among the most frequent reasons for seeking&#xD;
      medical attention in primary care. Although from predominantly viral origin, ARTIs are the&#xD;
      most important condition for the prescription of antibiotics (AB), mainly due to the&#xD;
      difficulty in primary care to differentiate between viral and bacterial etiology. Unnecessary&#xD;
      AB use increases drug expenditures, side effects and AB resistance. A novel approach is to&#xD;
      guide AB use by procalcitonin (ProCT), since serum levels are elevated in bacterial&#xD;
      infections but remain lower in viral infections and inflammatory diseases.&#xD;
&#xD;
      We aim to compare a strategy based on evidence-based guidelines with ProCT guided AB therapy&#xD;
      in ARTIs with respect to outcome (days with restriction) and AB use. Patients presenting with&#xD;
      ARTIs to primary care physicians and are intended to be treated with AB based on guidelines&#xD;
      will be included and randomized 1:1 either to standard management or to the ProCT guided&#xD;
      prescription of AB. All participating physicians will receive evidence-based guidelines for&#xD;
      the management of patients with ARTIs. Patients with ARTI and in need of ABs by physicians'&#xD;
      clinical judgment and with informed consent will be randomized to ProCT plus guidelines&#xD;
      (&quot;ProCT group&quot;) versus only guidelines guided AB treatment (&quot;control group&quot;). In patients&#xD;
      randomized to the ProCT group, the use of antibiotics will be more or less discouraged (&lt;0.1&#xD;
      or &lt;0.25 ug/L) or encouraged (&gt;0.5 or &gt;0.25 ug/L), respectively. A re-evaluation in patients&#xD;
      with ProCT (&lt;0.1 or &lt;0.25 ug/L) after 6 to 24 hours is mandatory. All patients will be&#xD;
      reassessed at day 3 and it is recommended to stop AB in the ProCT group as described above.&#xD;
      Structured phone interviews at days 14 and 28 will be done in all patients from both groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Acute respiratory tract infections (ARTI) (i.e. common cold, pharyngitis,&#xD;
      tonsillitis, rhinosinusitis, tracheo-bronchitis, otitis media, acute exacerbations of asthma&#xD;
      (AEA) and of chronic pulmonary disease (AECOPD), and community acquired pneumonia (CAP)), are&#xD;
      among the most frequent reasons for seeking medical attention in primary care. Although from&#xD;
      predominantly viral origin, ARTIs are the most important condition for the prescription of&#xD;
      antibiotics (AB), mainly due to the difficulty in primary care to differentiate between viral&#xD;
      and bacterial etiology. Unnecessary AB use increases drug expenditures, side effects and AB&#xD;
      resistance. A novel approach is to guide AB use by procalcitonin (ProCT), since serum levels&#xD;
      are elevated in bacterial infections but remain lower in viral infections and inflammatory&#xD;
      diseases.&#xD;
&#xD;
      Aim: To compare a strategy based on evidence-based guidelines with ProCT guided AB therapy in&#xD;
      ARTIs with respect to outcome (days with restriction) and AB use.&#xD;
&#xD;
      Design: Randomized, controlled trial with an open intervention. Patients presenting with&#xD;
      ARTIs to primary care physicians and are intended to be treated with AB based on guidelines&#xD;
      will be included and randomized 1:1 either to standard management or to the ProCT guided&#xD;
      prescription of AB.&#xD;
&#xD;
      Setting: Primary care providers in the Northwest of Switzerland from cantons with or without&#xD;
      drug self dispensation (Basel-Stadt and Baselland).&#xD;
&#xD;
      Patients: 18 years or older, with ARTI of &gt;1 and &lt;28 days duration and in need of ABs based&#xD;
      on the clinical judgment of the primary care physician. Excluded are patients without&#xD;
      informed consent, not fluent in German, with AB pretreatment in previous 28 days or severe&#xD;
      immune-suppression.&#xD;
&#xD;
      Endpoints: Primary: Days with restrictions from ARTI. Secondary: Rate of AB prescriptions,&#xD;
      days with AB use, symptoms from ARTI, relapse rate from ARTI within 28 days, days with side&#xD;
      effects from ABs and off work. Endpoints will be assessed at baseline, days 1 to 3 by the&#xD;
      physicians. Structured phone interviews at days 14 and 28 will be done in all patients from&#xD;
      both groups.&#xD;
&#xD;
      Intervention: All participating physicians will receive evidence-based guidelines for the&#xD;
      management of patients with ARTIs. Patients with ARTI and in need of ABs by physicians'&#xD;
      clinical judgment and with informed consent will be randomized to ProCT plus guidelines&#xD;
      (&quot;ProCT group&quot;) versus only guidelines guided AB treatment (&quot;control group&quot;). In patients&#xD;
      randomized to the ProCT group the use of antibiotics will be more or less discouraged (&lt;0.1&#xD;
      or &lt;0.25 ug/L) or encouraged (&gt;0.5 or &gt;0.25 ug/L), respectively. A re-evaluation in patients&#xD;
      with ProCT (&lt;0.1 or &lt;0.25 ug/L) after 6 to 24 hours is mandatory. All patients will be&#xD;
      reassessed at day 3 and it is recommended to stop AB in the ProCT group as described above.&#xD;
      Blood specimens for ProCT, taken from all patients, will be shipped by courier to the central&#xD;
      lab and results will be reported within 2 hours.&#xD;
&#xD;
      Variables and measurement: Physicians have to consecutively enroll all patients with ARTI in&#xD;
      whom they consider AB treatment. Baseline data on medical history and clinical items,&#xD;
      additional diagnostic tests, co-morbidity and final prescribed treatment will be collected.&#xD;
      The study will be conducted over a 12 month period in 2005.&#xD;
&#xD;
      Expected results: We assume noninferiority if at worst the new procedure leads to an increase&#xD;
      on average of one day with restrictions compared to standard procedure with a reduced total&#xD;
      AB use.&#xD;
&#xD;
      Our null hypothesis is: ProCT guided antibiotic management gives on average more than an&#xD;
      extra day with restrictions than standard procedure.&#xD;
&#xD;
      Alternative hypothesis: ProCT guided antibiotic management gives on average at most one day&#xD;
      with restrictions more than the standard procedure&#xD;
&#xD;
      Analyses: Analysis will be done based on the intention-to-treat principle. Sample size for&#xD;
      type I error rate of 5% and type II error rate of 10% (i.e. 90% power) = 171. With allowance&#xD;
      for a loss to followup of 10% the required sample size is 190 per treatment group. We intend&#xD;
      to gain 24 primary care physicians to recruit the total of 380 patients.&#xD;
&#xD;
      Significance: Because of the high prevalence of ARTIs, this study will offer potential for&#xD;
      improving the management of ARTIs in primary care by avoiding unnecessary ABs in patients&#xD;
      with ARTIs, along with the prevention of AB resistance. For these reasons, it has high&#xD;
      relevance for the Swiss health care system and for public health in Switzerland.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days with restrictions from ARTI</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of AB prescriptions</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days with AB use</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptoms from ARTI</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse rate from ARTI within 28 days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days with side effects from ABs and off work</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost-effectiveness</measure>
  </secondary_outcome>
  <enrollment>400</enrollment>
  <condition>Respiratory Tract Infections</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Procalcitonin guided antibiotic therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  ARTI of &gt;1 and &lt;28 days duration&#xD;
&#xD;
          -  In need of ABs based on the clinical judgment of the primary care physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients without informed consent&#xD;
&#xD;
          -  Not fluent in German&#xD;
&#xD;
          -  AB pretreatment in previous 28 days&#xD;
&#xD;
          -  Severe immune-suppression&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beat Muller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <state>CH</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, MÃ¼ller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004 Feb 21;363(9409):600-7.</citation>
    <PMID>14987884</PMID>
  </reference>
  <verification_date>January 2006</verification_date>
  <study_first_submitted>December 21, 2004</study_first_submitted>
  <study_first_submitted_qc>December 20, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2004</study_first_posted>
  <last_update_submitted>April 24, 2007</last_update_submitted>
  <last_update_submitted_qc>April 24, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2007</last_update_posted>
  <keyword>common cold</keyword>
  <keyword>pharyngitis</keyword>
  <keyword>tonsillitis</keyword>
  <keyword>rhinosinusitis</keyword>
  <keyword>tracheo-bronchitis</keyword>
  <keyword>otitis media</keyword>
  <keyword>acute exacerbations of asthma</keyword>
  <keyword>acute exacerbations of chronic pulmonary disease</keyword>
  <keyword>community acquired pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

